SecBot SecBot
SECBOTREPLAY Home › Report › TXG

TXG · The Federal Circuit affirmed PTAB decisions invalidating all claims of…

10x Genomics, Inc. · COURT-RULING filed Aug 18, 2026 at 20:00 ET

At the news

BEARISHIMPACT 7/10

COURT-RULING filed Aug 18, 2026 at 20:00 ET

The Federal Circuit affirmed PTAB decisions invalidating all claims of three 10x Genomics patents (’981, ’197, ’013) as obvious in IPRs brought by Parse Biosciences. This is a significant loss for 10x Genomics' patent portfolio covering core single-cell analysis methods, weakening its competitive moat and potentially exposing it to increased competition from Parse and other rivals. The ruling is final and nonprecedential but represents a material erosion of 10x's IP barriers in its key market.

  • Federal Circuit affirmed PTAB decisions that all claims of U.S. Patent Nos. 10,155,981, 10,240,197, and 10,697,013 are unpatentable as obvious.
  • The three patents cover methods for analyzing nucleic acids from single cells, a core technology for 10x Genomics.
  • The court rejected all four of 10x's challenges to the Board's motivation-to-combine and disclosure findings.
  • The ruling is a final, nonprecedential disposition from the Federal Circuit, with no further appeal within the patent office.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access